A groundbreaking study published in The New England Journal of Medicine demonstrates that genetically engineered allogeneic islet cells can restore insulin secretion in a type 1 diabetes patient without triggering an immune response or requiring immunosuppressive therapy. Led by Per-Ola Carlsson from Uppsala University, researchers utilized CRISPR technology to modify the islet cells, enabling 66% of them to produce insulin. Notably, the participant's glycated hemoglobin levels dropped significantly, and there were no immune activation signs during the 12-week follow-up, indicating potential for long-term diabetes treatment.

Source: The New England Journal of Medicine